Biovica: The Medicare price is set at USD 322 already from 1 January 2024 - Redeye

The early CMS price decision is good news and the price is in our view within the expected DiviTum price range for the Medicare channel. In 2024 and part of 2025 we still expect most of the sales to be related to Direct Bill sales and Hospital Agreement sales and the main difference during calendar 2024 is probably that Medicare related sales will be faster and more efficient. Once larger volumes are established we expect the Medicare related sales to approach 40-50%. The price level in Direct Bill and Hospital Agreement sales will be significantly above USD 400 and hence we expect a scenario where increasing volumes will result in an average price gravitating toward the USD 400 level.

Länk till analysen i sin helhet: https://www.redeye.se/research/962018/biovica-the-medicare-price-is-set-at-usd-322-already-from-1-january-2024?utm_source=finwire&utm_medium=RSS